Goodpasture antigen binding protein and its detection

Details Goodpasture antigen binding protein and its detection Goodpasture antigen binding protein and its detection

2011-05-03

2011-05-03

Haddad, Maher M (Department: 1644)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007920

Reexamination Certificate

active

07935492

ABSTRACT:
The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.

REFERENCES:
patent: 5625048 (1997-04-01), Tsien et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 6124128 (2000-09-01), Tsien et al.
patent: 6579969 (2003-06-01), Saus
patent: 7147855 (2006-12-01), Saus et al.
patent: 7186527 (2007-03-01), Saus
patent: 7189517 (2007-03-01), Saus
patent: 7326768 (2008-02-01), Saus et al.
patent: 2004/0175758 (2004-09-01), Saus et al.
patent: 2007/0178540 (2007-08-01), Saus
patent: WO 00/50607 (2000-08-01), None
patent: WO 02/061430 (2002-08-01), None
patent: WO 2004/070025 (2004-08-01), None
Alpy and Tomasetto (2005), “Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.” J. Cell Sci. 118, 2791-2801.
Balow, J.E., Boumpas, D. T., and Austin III, H.A. “Systemic Lupus Erythematosus and the kidney”. Systemic Lupus Erythematosus. Edited by Lahita RG. San Diego, Academic Press, 1999, pp. 657-685.
Bendtsen et al. (2004), “Feature-based prediction of non-classical and leaderless protein secretion.” Protein Eng. Des. Sel. 17: 349-356.
Borza et al. (2005), “Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanisms for immune privilege and autoimmune pathogenesis.” J. Biol. Chem. 280: 27147-27154.
Calvete et al. (2006), “Conformational diversity of the Goodpasture antigen, the noncollagenous-1 domain of the alpha3 chain of collagen IV.” Proteomics 6: S237-S244.
Donadio and Grande (2002), “IgA nephropathy.” N. Engl. J. Med. 347: 738-748.
Dowler et al. (2000), “Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities.” Biochem. J. 351: 19-31.
Evans et al. (1995), “Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells.” J. Immunol. Meth. 184: 123-38.
Fugmann et al. (2007), “Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein.” J. Cell Biol. 178: 15-22.
Granero et al. (2005), “A human-specific TNF-responsive promoter for Goodpasture antigen-binding protein.” FEBS J. 272: 5291-5305.
Granero-Moltó et al. (2008), “Goodpasture antigen-binding protein and its spliced variant, ceramide transfer protein, have different functions in the modulation of apoptosis during zebrafish development.” J. Biol. Chem. 283(29): 20495-504.
Haas M. “IgA Nephropathy and Henoch-Schönlein Purpura Nephritis”. Heptinstall's Pathology of the Kidney. Edited by Jennette JC, Olson JL, Schwartz MM, Silva FG. Philadelphia, Lippincott Williams & Wilkins Publishers 2007, pp. 423-486.
Hanada et al. (2003), “Molecular machinery for non-vesicular trafficking of ceramide.” Nature 426: 803-809.
Hudson et al. (2003), “Alport's syndrome, Goodpasture's syndrome, and type IV collagen.” N. Engl. J. Med. 348: 2543-2556.
Kanekura et al. (2006), “Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8).” J. Biol. Chem. 281: 30223-30233.
Kawano et al. (2006), “Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT.” J. Biol. Chem. 281: 30279-30288.
Kumagai et al. (2007), “Interorganelle trafficking of ceramide is regulated by phosphorylation-dependent cooperativity between the PH and START domains of CERT.” J. Biol. Chem. 282: 17758-17766.
Lamour et al. (2007), “Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis.” J. Lipid Res. 48: 1293-1304.
Lemmon and Ferguson (2000), “Signal-dependent membrane targeting by pleckstrin homology (PH) domains.” Biochem J. 350: 1-18.
Loewen et al. (2003), “A conserved ER targeting motif in three families of lipid binding proteins and in Opi1p binds VAP.” EMBO J. 22: 2025-2035.
Marquina et al. (2004), “Inhibition of B cell death causes the development of an IgA nephropathy in (New Zealand white x C57BL/6)F1-bcl-2 transgenic mice.” J. Immunol. 172: 7177-7185.
Netzer et al. (1999), “The goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain.” J. Biol. Chem. 274: 11267-11274.
Ni and Lee (2007), “ER chaperones in mammalian development and human diseases.” FEBS Lett. 581: 3641-3651.
Peabody (1989), “Translation initiation at non-AUG triplets in mammalian cells.” J. Biol. Chem. 264: 5031-5035.
Perry and Ridgway (2006), “Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein.” Mol. Biol. Cell. 17: 2604-2616.
Raya et al. (1999), “Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen.” J. Biol. Chem. 274: 12642-12649.
Raya et al. (2000), “Goodpasture antigen-binding protein, the kinase that phosphorylates the goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis.” J. Biol. Chem. 275: 40392-40399.
Revert et al. (1995), “Phosphorylation of the Goodpasture antigen by type A protein kinases.” J. Biol. Chem. 270: 13254-13261.
Revert et al. (2007), “Increased Goodpasture antigen-binding protein expression induces type IV collagen disorganization and deposit of immunoglobulin A in glomerular basement membrane.” Am. J. Pathol. 171: 1419-1430.
Revert et al. (2008), “Goodpasture antigen-binding protein is a soluble exportable protein that interacts with type IV collagen. Identification of novel membrane-bound isoforms.” J. Biol. Chem. 283: 30246-55.
Rual et al. (2005), “Towards a proteome-scale map of the human protein-protein interaction network.” Nature 437: 1173-1178.
Soccio and Breslow (2003), “StAR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism.” J. Biol. Chem. 278: 22183-22186.
Strasser et al. (1991), “Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.” Proc. Natl. Acad. Sci. USA 88: 8661-8665.
Swanton et al. (2007), “Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.” Cancer Cell 11: 498-512.
Touriol et al. (2003), “Generation of protein isoform diversity by alternative initiation of translation at non-AUG condons.” Biol. Cell. 95: 169-178.
Wyles et al. (2002), “Vesicle-associated membrane protein-associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify export from the endoplasmic reticulum.” J. Biol. Chem. 277: 29908-29918.
Yang and Li (2005), “Roles of heat shock protein gp96 in the ER quality control: redundant or unique function?” Mol. Cells. 20: 173-182.
Yoshida et al. (2001), “XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor.” Cell 107: 881-891.

Affiliated with

Also associated with

Rating

Goodpasture antigen binding protein and its detection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Goodpasture antigen binding protein and its detection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Goodpasture antigen binding protein and its detection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2659046